DECOY THERAPEUTICS INC (DCOY) Stock Fundamental Analysis

NASDAQ:DCOY • US79400X5032

0.7388 USD
-0.01 (-1.51%)
At close: Feb 13, 2026
0.7105 USD
-0.03 (-3.83%)
After Hours: 2/13/2026, 8:02:31 PM
Fundamental Rating

1

DCOY gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 522 industry peers in the Biotechnology industry. DCOY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DCOY has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year DCOY has reported negative net income.
  • DCOY had a negative operating cash flow in the past year.
  • DCOY had negative earnings in each of the past 5 years.
  • DCOY had a negative operating cash flow in each of the past 5 years.
DCOY Yearly Net Income VS EBIT VS OCF VS FCFDCOY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -82.08%, DCOY is not doing good in the industry: 68.39% of the companies in the same industry are doing better.
  • With a Return On Equity value of -117.81%, DCOY perfoms like the industry average, outperforming 41.19% of the companies in the same industry.
Industry RankSector Rank
ROA -82.08%
ROE -117.81%
ROIC N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
DCOY Yearly ROA, ROE, ROICDCOY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for DCOY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DCOY Yearly Profit, Operating, Gross MarginsDCOY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

5

2. Health

2.1 Basic Checks

  • DCOY has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DCOY has been increased compared to 5 years ago.
  • Compared to 1 year ago, DCOY has a worse debt to assets ratio.
DCOY Yearly Shares OutstandingDCOY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K
DCOY Yearly Total Debt VS Total AssetsDCOY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -20.01, we must say that DCOY is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -20.01, DCOY is not doing good in the industry: 82.95% of the companies in the same industry are doing better.
  • DCOY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.01
ROIC/WACCN/A
WACCN/A
DCOY Yearly LT Debt VS Equity VS FCFDCOY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 3.28 indicates that DCOY has no problem at all paying its short term obligations.
  • The Current ratio of DCOY (3.28) is worse than 61.30% of its industry peers.
  • A Quick Ratio of 3.28 indicates that DCOY has no problem at all paying its short term obligations.
  • DCOY has a Quick ratio (3.28) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.28
Quick Ratio 3.28
DCOY Yearly Current Assets VS Current LiabilitesDCOY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

0

3. Growth

3.1 Past

  • DCOY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.10%, which is quite impressive.
EPS 1Y (TTM)68.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-126.98%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DCOY Yearly Revenue VS EstimatesDCOY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2026 2M 4M 6M 8M 10M
DCOY Yearly EPS VS EstimatesDCOY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 -50K -100K -150K

0

4. Valuation

4.1 Price/Earnings Ratio

  • DCOY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year DCOY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DCOY Price Earnings VS Forward Price EarningsDCOY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DCOY Per share dataDCOY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • DCOY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

DECOY THERAPEUTICS INC

NASDAQ:DCOY (2/13/2026, 8:02:31 PM)

After market: 0.7105 -0.03 (-3.83%)

0.7388

-0.01 (-1.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-19
Inst Owners5.13%
Inst Owner ChangeN/A
Ins Owners0.64%
Ins Owner ChangeN/A
Market Cap4.71M
Revenue(TTM)N/A
Net Income(TTM)-5.00M
Analysts43.33
Price TargetN/A
Short Float %18.42%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.11
P/tB 1.11
EV/EBITDA N/A
EPS(TTM)-39.18
EYN/A
EPS(NY)-9.35
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS0.67
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.08%
ROE -117.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.28
Quick Ratio 3.28
Altman-Z -20.01
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.05%
EPS Next Y-126.98%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.38%
OCF growth 3YN/A
OCF growth 5YN/A

DECOY THERAPEUTICS INC / DCOY FAQ

What is the fundamental rating for DCOY stock?

ChartMill assigns a fundamental rating of 1 / 10 to DCOY.


Can you provide the valuation status for DECOY THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to DECOY THERAPEUTICS INC (DCOY). This can be considered as Overvalued.


How profitable is DECOY THERAPEUTICS INC (DCOY) stock?

DECOY THERAPEUTICS INC (DCOY) has a profitability rating of 0 / 10.


How financially healthy is DECOY THERAPEUTICS INC?

The financial health rating of DECOY THERAPEUTICS INC (DCOY) is 5 / 10.


Is the dividend of DECOY THERAPEUTICS INC sustainable?

The dividend rating of DECOY THERAPEUTICS INC (DCOY) is 0 / 10 and the dividend payout ratio is 0%.